Skip to main content
Premium Trial:

Request an Annual Quote

Life Tech, LGC Forensics Ink Distribution Deal for Forensic DNA System

NEW YORK (GenomeWeb News) – Life Technologies today announced a distribution deal covering LGC Forensics' portable system for determining the quality of human DNA for forensics applications.

LGC's ParaDNA system facilitates the identification of samples that are suitable for more in-depth analysis by indicating whether samples contain usable DNA profiles. According to Life Tech, the ParaDNA platform is faster and more economical than other existing methods and helps reduce laboratory backlogs and processing turnaround times.

Carlsbad, Calif.-based Life Tech said that the deal with LGC is the second in a series of "Rapid DNA" products that the firm plans to introduce "to expand the landscape beyond traditional Rapid DNA systems." In September, Life Tech launched its GlobalFiler and GlobalFiler Express STR analysis kits for human identification and forensic applications.

The kits were the first to include all 24 STR loci commonly used in different combinations in the US, Europe, and other geographies for human identification, GenomeWeb Daily News sister publication PCR Insider reported at the time.

"We know that DNA profiling can help establish whether or not there is a link between a suspect and a crime," Mark Dearden, business unit director of ParaDNA for Teddington, UK-based LGC Forensics, said in a statement. "ParaDNA enables a quick and simple, on-the-spot, presumptive DNA screen to complement submissions policies — and could save significant time and cost in the investigative process."

Financial and other terms of the deal were not disclosed.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.